Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Pharvaris N V's Competitiveness

Name: Pharvaris N V Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Pharvaris N V (PHVS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2025

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/PHVS/competitors                    

                        https://api.csimarket.com/api/v1/companies/PHVS/relationships                    

                        https://api.csimarket.com/api/v1/companies/PHVS/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Pharvaris N V's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Pharvaris N v	-	-	-	Yes
High-Confidence Competitors (2)
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

PHVS Stock Performance relative to its Competitors

PHVS Competitors (weighted) Percent change over the selected range

Pharvaris N V's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(1 of 2)

Similar-Size
(6 of 9)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Pharvaris N v	30.00 %	Outperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (2)	40.4%	63.2%
Similar-Size Competitors (9)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Pharvaris N V's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

PHVS Stock Performance relative to High-Confidence Competitors

PHVS High-Confidence Competitors (equal-weighted, 2) Percent change over the selected range

PHVS Stock Performance relative to Similar-Size Competitors

PHVS Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Pharvaris N V's Comment on Competition and Industry Peers

The company faces competitive risks related to patent protection and intellectual property agreements, particularly involving BRAIN Biotech AG, the successor to AnalytiCon Discovery GmbH. Competitors may hold patents that restrict the company's ability to commercialize its products. Clinical trial enrollment could be affected by competitors conducting trials for the same indications, impacting patient availability. Orphan drug exclusivity may not prevent competitors from developing different products targeting the same indications. Regulatory compliance and potential enforcement actions may influence the company's competitive position. Additionally, advertising and marketing activities could result in litigation initiated by competitors. Competitors identified in company filings include AnalytiCon Discovery GmbH and BRAIN Biotech AG.

Competitor data is not yet available for Pharvaris N V.

Pharvaris N V's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Kalvista Pharmaceuticals Inc	Named by the company	85%	2022 to 2026	3
BRAIN Biotech AG	Named by the company	85%	2022 to 2026	3
Intellia Therapeutics Inc	Named by the company	85%	2022 to 2026	3
AnalytiCon Discovery GmbH	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Pharvaris N V's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.